ABS0527 EFFECT OF ABATACEPT ON EROSIVE PSORIATIC ARTHRITIS – RESULTS FROM A PROSPECTIVE INTERVENTIONAL TRIAL (ABEPSA)

Abdülkerim Temiz(Universitätsklinikum Erlangen), A. Kleyer(Universitätsklinikum Erlangen), Melek Yalçın Mutlu(Bakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi), K. Tascilar(Universitätsklinikum Erlangen), Giulia Corte(Friedrich-Alexander-Universität Erlangen-Nürnberg), G. Schett(Universitätsklinikum Erlangen), Filippo Fagni(Universitätsklinikum Erlangen), Jürgen Rech(Universitätsklinikum Erlangen), D. Simon(Friedrich-Alexander-Universität Erlangen-Nürnberg)
Annals of the Rheumatic Diseases
June 1, 2025
10.1016/j.ard.2025.06.1385
Cited by 0

Related Papers

CD19-CAR T-cell therapy induces deep tissue depletion of B cells
|Annals of the Rheumatic Diseases|2024|170
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study
|Arthritis & Rheumatology|2021|165
Bispecific T cell engager therapy for refractory rheumatoid arthritis
|Nature Medicine|2024|147
The Role of Dietary Fiber in Rheumatoid Arthritis Patients: A Feasibility Study
|Nutrients|2019|134
Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial
|The Lancet|2024|134